Largest biotech companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 20 biotech companies in the United States ranked by net assets, at CHF 19.2B, ahead of Biogen (CHF 15.4B) and Amgen (CHF 7.3B). Figures as of 19 Nov 2026, 23:27 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Gilead SciencesCHF 19.2B
- Median
- CHF 1.4B
- Combined market value
- CHF 620.3B
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | CHF 19.2B | CHF 174.3B | CHF 140.55 | 1.45% down | 35% up | ||
| 2 | BiogenBIIB · Health Care | CHF 15.4B | CHF 30.8B | CHF 208.57 | 1.70% down | 49% up | ||
| 3 | AmgenAMGN · Health Care | CHF 7.3B | CHF 200.3B | CHF 370.36 | 1.14% down | 32% up | ||
| 4 | ModernaMRNA · Health Care | CHF 7.3B | CHF 68.1B | CHF 168.23 | 1.29% up | 780% up | ||
| 5 | Neurocrine BiosciencesNBIX · Health Care | CHF 2.7B | CHF 13.4B | CHF 132.16 | 3.85% down | 17% up | ||
| 6 | VaxcytePCVX · Health Care | CHF 2.3B | CHF 7.8B | CHF 49.25 | 0.27% down | 23% up | ||
| 7 | ExelixisEXEL · Health Care | CHF 1.8B | CHF 13.6B | CHF 55.56 | 3.60% down | 63% up | ||
| 8 | Bio-TechneTECH · Health Care | CHF 1.8B | CHF 9.6B | CHF 61.36 | 0.07% down | 24% up | ||
| 9 | RepligenRGEN · Health Care | CHF 1.8B | CHF 9.2B | CHF 143.72 | 1.38% down | 12% up | ||
| 10 | Revolution MedicinesRVMD · Health Care | CHF 1.4B | CHF 29.1B | CHF 134.56 | 0.24% down | 129% up | ||
| 11 | Kymera TherapeuticsKYMR · Health Care | CHF 1.3B | CHF 8.6B | CHF 100.76 | 1.44% down | 87% up | ||
| 12 | Krystal BiotechKRYS · Health Care | CHF 1B | CHF 7.9B | CHF 266.55 | 0.15% up | 54% up | ||
| 13 | ImmunovantIMVT · Health Care | CHF 719.6M | CHF 5.7B | CHF 27.45 | 1.96% down | 46% up | ||
| 14 | CG OncologyCGON · Health Care | CHF 635.2M | CHF 6.2B | CHF 69.12 | 2.38% up | 97% up | ||
| 15 | Twist BioscienceTWST · Health Care | CHF 399.2M | CHF 6.4B | CHF 94.21 | 4.07% down | 346% up | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | CHF 207.2M | CHF 5.2B | CHF 42.51 | 4.94% up | 26% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | CHF 184.7M | CHF 3.8B | CHF 23.67 | 1.44% down | 74% up | ||
| 18 | Kodiak SciencesKOD · Health Care | CHF 132.8M | CHF 5.4B | CHF 82.63 | 0.09% up | 399% up | ||
| 19 | Halozyme TherapeuticsHALO · Health Care | CHF 41.2M | CHF 9B | CHF 78.52 | 2.88% down | 39% up | ||
| 20 | ImmunityBioIBRX · Health Care | -CHF 422.4M | CHF 5.9B | CHF 5.54 | 1.94% down | 232% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8440 CHF).
Questions and answers
Which biotech companies in the United States rank first by net assets?
Gilead Sciences (CHF 19.2B), Biogen (CHF 15.4B) and Amgen (CHF 7.3B) are the top three of the 20 biotech companies in the United States ranked by net assets as of 19 Nov 2026, 23:27 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by net assets.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by net assets have a combined market value of CHF 620.3B as of 19 Nov 2026, 23:27 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies in the United States by net assets”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.